Geovax Labs Stock Performance
| GOVXW Stock | USD 0.13 0.00 0.00% |
GeoVax Labs holds a performance score of 8 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 1.05, which attests to a somewhat significant risk relative to the market. GeoVax Labs returns are very sensitive to returns on the market. As the market goes up or down, GeoVax Labs is expected to follow. Use GeoVax Labs sortino ratio, semi variance, day typical price, as well as the relationship between the value at risk and kurtosis , to analyze future returns on GeoVax Labs.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in GeoVax Labs are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, GeoVax Labs showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 27.6 M |
GeoVax |
GeoVax Labs Relative Risk vs. Return Landscape
If you would invest 10.00 in GeoVax Labs on November 4, 2024 and sell it today you would earn a total of 3.00 from holding GeoVax Labs or generate 30.0% return on investment over 90 days. GeoVax Labs is currently producing 1.6526% returns and takes up 15.969% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than GeoVax, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
GeoVax Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GeoVax Labs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GeoVax Labs, and traders can use it to determine the average amount a GeoVax Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1035
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | GOVXW | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.97 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.65 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 8 92% of assets perform better |
Based on monthly moving average GeoVax Labs is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GeoVax Labs by adding it to a well-diversified portfolio.
GeoVax Labs Fundamentals Growth
GeoVax Stock prices reflect investors' perceptions of the future prospects and financial health of GeoVax Labs, and GeoVax Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeoVax Stock performance.
| Return On Equity | -3.62 | ||||
| Return On Asset | -1.34 | ||||
| Operating Margin | (16.84) % | ||||
| EBITDA | (26.67 M) | ||||
| Cash And Equivalents | 710.68 K | ||||
| Cash Per Share | 0.92 X | ||||
| Total Debt | 3.52 M | ||||
| Book Value Per Share | 2.92 X | ||||
| Cash Flow From Operations | (25.17 M) | ||||
| Total Asset | 9.28 M | ||||
| Retained Earnings | (104.36 M) | ||||
About GeoVax Labs Performance
Evaluating GeoVax Labs' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if GeoVax Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if GeoVax Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia. Geovax Labs is traded on NASDAQ Exchange in the United States.Things to note about GeoVax Labs performance evaluation
Checking the ongoing alerts about GeoVax Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GeoVax Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeoVax Labs is way too risky over 90 days horizon | |
| GeoVax Labs has some characteristics of a very speculative penny stock | |
| GeoVax Labs appears to be risky and price may revert if volatility continues | |
| GeoVax Labs has high likelihood to experience some financial distress in the next 2 years | |
| GeoVax Labs has accumulated 3.52 M in total debt. GeoVax Labs has a current ratio of 0.33, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about GeoVax Labs' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (25.97 M) with loss before overhead, payroll, taxes, and interest of (21.58 M). | |
| GeoVax Labs has accumulated about 710.68 K in cash with (25.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| GeoVax Labs has a frail financial position based on the latest SEC disclosures |
- Analyzing GeoVax Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeoVax Labs' stock is overvalued or undervalued compared to its peers.
- Examining GeoVax Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeoVax Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeoVax Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeoVax Labs' stock. These opinions can provide insight into GeoVax Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GeoVax Stock Analysis
When running GeoVax Labs' price analysis, check to measure GeoVax Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeoVax Labs is operating at the current time. Most of GeoVax Labs' value examination focuses on studying past and present price action to predict the probability of GeoVax Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeoVax Labs' price. Additionally, you may evaluate how the addition of GeoVax Labs to your portfolios can decrease your overall portfolio volatility.